Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer

Alberto Riccardi, Silvia Brugnatelli, Monica Giordano, Marco Danova, Palma Pugliese, Carmine Tinelli, Catherine Klersy, Antonella Richetti, Sergio Fava, Giuseppe Nastasi, Elena Rinaldi, Vittorio Fregoni, Andrea De Monte, Giovanni Trotti, Antonella Bovio, Edoardo Ascari

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims and background: The neutropenia induced by six courses of an intensified FEC regimen is expected to be checked by early primary administration of G-CSF which is stopped eight days before the next chemotherapy course. Less information is available about megakaryocytic and erythroid toxicity over six courses. Methods and study design: Sixty-six consecutive patients with metastatic breast cancer completed six courses of a randomized treatment with two FEC regimens administered every 21 days, in which 600 mg/m2 of cyclophosphamide and 5-FU was associated with 60 or 120 mg/m2 of epirubicin (60FEC, 35 patients, vs 120FEC, 31 patients). 120FEC was supported by early primary G-CSF (days 4 to 13). Blood counts were obtained seven times during each course. Results: The non-hematologic toxicity over 364 courses was similar in 60FEC and 120FEC. No cumulative hematologic toxicity was observed for white blood cells (WBC) and platelets (PLT), while for hemoglobin (Hb) a somewhat higher cumulative toxicity was observed with 120FEC than with 60FEC. WBC, PLT and Hb grade III-IV toxicity occurred in 40.1% and 45.6% (P=ns), in 23.1% and 0.8% (P

Original languageEnglish
Pages (from-to)540-546
Number of pages7
JournalTumori
Volume84
Issue number5
Publication statusPublished - 1998

Fingerprint

Epirubicin
Granulocyte Colony-Stimulating Factor
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Hemoglobins
Leukocytes
Blood Platelets
Neutropenia
Therapeutics

Keywords

  • Advanced breast cancer
  • Dose intensity
  • Epirubicin
  • G-CSF
  • Myeloprotection

ASJC Scopus subject areas

  • Cancer Research

Cite this

Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. / Riccardi, Alberto; Brugnatelli, Silvia; Giordano, Monica; Danova, Marco; Pugliese, Palma; Tinelli, Carmine; Klersy, Catherine; Richetti, Antonella; Fava, Sergio; Nastasi, Giuseppe; Rinaldi, Elena; Fregoni, Vittorio; De Monte, Andrea; Trotti, Giovanni; Bovio, Antonella; Ascari, Edoardo.

In: Tumori, Vol. 84, No. 5, 1998, p. 540-546.

Research output: Contribution to journalArticle

Riccardi, A, Brugnatelli, S, Giordano, M, Danova, M, Pugliese, P, Tinelli, C, Klersy, C, Richetti, A, Fava, S, Nastasi, G, Rinaldi, E, Fregoni, V, De Monte, A, Trotti, G, Bovio, A & Ascari, E 1998, 'Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer', Tumori, vol. 84, no. 5, pp. 540-546.
Riccardi, Alberto ; Brugnatelli, Silvia ; Giordano, Monica ; Danova, Marco ; Pugliese, Palma ; Tinelli, Carmine ; Klersy, Catherine ; Richetti, Antonella ; Fava, Sergio ; Nastasi, Giuseppe ; Rinaldi, Elena ; Fregoni, Vittorio ; De Monte, Andrea ; Trotti, Giovanni ; Bovio, Antonella ; Ascari, Edoardo. / Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. In: Tumori. 1998 ; Vol. 84, No. 5. pp. 540-546.
@article{46a7373937e84f5bb89d7182ea68c3e3,
title = "Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer",
abstract = "Aims and background: The neutropenia induced by six courses of an intensified FEC regimen is expected to be checked by early primary administration of G-CSF which is stopped eight days before the next chemotherapy course. Less information is available about megakaryocytic and erythroid toxicity over six courses. Methods and study design: Sixty-six consecutive patients with metastatic breast cancer completed six courses of a randomized treatment with two FEC regimens administered every 21 days, in which 600 mg/m2 of cyclophosphamide and 5-FU was associated with 60 or 120 mg/m2 of epirubicin (60FEC, 35 patients, vs 120FEC, 31 patients). 120FEC was supported by early primary G-CSF (days 4 to 13). Blood counts were obtained seven times during each course. Results: The non-hematologic toxicity over 364 courses was similar in 60FEC and 120FEC. No cumulative hematologic toxicity was observed for white blood cells (WBC) and platelets (PLT), while for hemoglobin (Hb) a somewhat higher cumulative toxicity was observed with 120FEC than with 60FEC. WBC, PLT and Hb grade III-IV toxicity occurred in 40.1{\%} and 45.6{\%} (P=ns), in 23.1{\%} and 0.8{\%} (P",
keywords = "Advanced breast cancer, Dose intensity, Epirubicin, G-CSF, Myeloprotection",
author = "Alberto Riccardi and Silvia Brugnatelli and Monica Giordano and Marco Danova and Palma Pugliese and Carmine Tinelli and Catherine Klersy and Antonella Richetti and Sergio Fava and Giuseppe Nastasi and Elena Rinaldi and Vittorio Fregoni and {De Monte}, Andrea and Giovanni Trotti and Antonella Bovio and Edoardo Ascari",
year = "1998",
language = "English",
volume = "84",
pages = "540--546",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer

AU - Riccardi, Alberto

AU - Brugnatelli, Silvia

AU - Giordano, Monica

AU - Danova, Marco

AU - Pugliese, Palma

AU - Tinelli, Carmine

AU - Klersy, Catherine

AU - Richetti, Antonella

AU - Fava, Sergio

AU - Nastasi, Giuseppe

AU - Rinaldi, Elena

AU - Fregoni, Vittorio

AU - De Monte, Andrea

AU - Trotti, Giovanni

AU - Bovio, Antonella

AU - Ascari, Edoardo

PY - 1998

Y1 - 1998

N2 - Aims and background: The neutropenia induced by six courses of an intensified FEC regimen is expected to be checked by early primary administration of G-CSF which is stopped eight days before the next chemotherapy course. Less information is available about megakaryocytic and erythroid toxicity over six courses. Methods and study design: Sixty-six consecutive patients with metastatic breast cancer completed six courses of a randomized treatment with two FEC regimens administered every 21 days, in which 600 mg/m2 of cyclophosphamide and 5-FU was associated with 60 or 120 mg/m2 of epirubicin (60FEC, 35 patients, vs 120FEC, 31 patients). 120FEC was supported by early primary G-CSF (days 4 to 13). Blood counts were obtained seven times during each course. Results: The non-hematologic toxicity over 364 courses was similar in 60FEC and 120FEC. No cumulative hematologic toxicity was observed for white blood cells (WBC) and platelets (PLT), while for hemoglobin (Hb) a somewhat higher cumulative toxicity was observed with 120FEC than with 60FEC. WBC, PLT and Hb grade III-IV toxicity occurred in 40.1% and 45.6% (P=ns), in 23.1% and 0.8% (P

AB - Aims and background: The neutropenia induced by six courses of an intensified FEC regimen is expected to be checked by early primary administration of G-CSF which is stopped eight days before the next chemotherapy course. Less information is available about megakaryocytic and erythroid toxicity over six courses. Methods and study design: Sixty-six consecutive patients with metastatic breast cancer completed six courses of a randomized treatment with two FEC regimens administered every 21 days, in which 600 mg/m2 of cyclophosphamide and 5-FU was associated with 60 or 120 mg/m2 of epirubicin (60FEC, 35 patients, vs 120FEC, 31 patients). 120FEC was supported by early primary G-CSF (days 4 to 13). Blood counts were obtained seven times during each course. Results: The non-hematologic toxicity over 364 courses was similar in 60FEC and 120FEC. No cumulative hematologic toxicity was observed for white blood cells (WBC) and platelets (PLT), while for hemoglobin (Hb) a somewhat higher cumulative toxicity was observed with 120FEC than with 60FEC. WBC, PLT and Hb grade III-IV toxicity occurred in 40.1% and 45.6% (P=ns), in 23.1% and 0.8% (P

KW - Advanced breast cancer

KW - Dose intensity

KW - Epirubicin

KW - G-CSF

KW - Myeloprotection

UR - http://www.scopus.com/inward/record.url?scp=0031673176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031673176&partnerID=8YFLogxK

M3 - Article

C2 - 9862513

AN - SCOPUS:0031673176

VL - 84

SP - 540

EP - 546

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -